Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 20/20 | 1.00 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14359899 | 0.96 | PDE2A (1.00) | PDE2APDE10A | |
| SCHEMBL15544428 | 0.93 | PDE2A (1.00) | PDE2APDE10A | |
| SCHEMBL14359687 | 0.87 | PDE2A (1.00) | PDE2APDE10A | |
| SCHEMBL12502200 | 0.87 | PDE2A (1.00) | PDE2APDE10A | |
| SCHEMBL15737929 | 0.86 | PDE2A (0.93) | PDE2APDE10A | |
| SCHEMBL14359707 | 0.86 | PDE2A (1.00) | PDE2APDE10A | |
| SCHEMBL14362134 | 0.85 | PDE2A (0.83) | PDE2APDE10A | |
| SCHEMBL14362062 | 0.85 | PDE2A (0.86) | PDE2APDE10A | |
| SCHEMBL14361964 | 0.85 | PDE2A (1.00) | PDE2APDE10A | |
| SCHEMBL12502641 | 0.85 | PDE2A (1.00) | PDE2APDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2723744-B1 | 1-ARYL-4-METHYL-[1,2,4]TRIAZOLO[4,3-a]QUINOXALINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2016-03-23 | — | — | EP | claimed |
| US-20140147386-A1 | 1-ARYL-4-METHYL-[1,2,4]TRIAZOLO[4,3-a]QUINOXALINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2014-05-29 | — | — | US | claimed |
| EP-2863909-B1 | COMBINATIONS COMPRISING 4-METHYL-[1,2,4]TRIAZOLO[4,3-A]QUINOXALINE COMPOUNDS AS PDE 2 INHIBITORS AND PDE 10 INHIBITORS FOR USE IN THE TREATMENT OF NEUROLOGICAL OR METABOLIC DISORDERS | JANSSEN PHARMACEUTICA NV (BE) | 2020-11-04 | — | — | EP | disclosed |
| US-10604523-B2 | 1-aryl-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline derivatives | JANSSEN PHARMACEUTICA NV (BE) | 2020-03-31 | — | — | US | disclosed |
| US-9669035-B2 | Combinations comprising PDE 2 inhibitors such as 1-aryl-4-methyl-[1,2,4]triazolo-[4,3-A]]quinoxaline compounds and PDE 10 inhibitors for use in the treatment of neurological of metabolic disorders | JANSSEN PHARMACEUTICA NV (BE) | 2017-06-06 | — | — | US | disclosed |
| EP-2723744-B1 | 1-ARYL-4-METHYL-[1,2,4]TRIAZOLO[4,3-a]QUINOXALINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2016-03-23 | — | — | EP | disclosed |
| US-20150366873-A1 | COMBINATIONS COMPRISING PDE 2 INHIBITORS SUCH AS 1-ARYL-4-METHYL-[1,2,4]TRIAZOLO-[4,3-A]]QUINOXALINE COMPOUNDS AND PDE 10 INHIBITORS FOR USE IN THE TREATMENT OF NEUROLOGICAL OF METABOLIC DISORDERS | JANSSEN PHARMACEUTICA NV (BE) | 2015-12-24 | — | — | US | disclosed |
| EP-2863909-A1 | COMBINATIONS COMPRISING PDE 2 INHIBITORS SUCH AS 1-ARYL-4-METHYL- [1,2,4]TRIAZOLO [4,3-A]QUINOXALINE COMPOUNDS AND PDE 10 INHIBITORS FOR USE IN THE TREATMENT OF NEUROLOGICAL OR METABOLIC DISORDERS | Janssen Pharmaceutica N.V. (BE) | 2015-04-29 | — | — | EP | disclosed |
| US-20140147386-A1 | 1-ARYL-4-METHYL-[1,2,4]TRIAZOLO[4,3-a]QUINOXALINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2014-05-29 | — | — | US | disclosed |
| WO-2014001314-A1 | COMBINATIONS COMPRISING PDE 2 INHIBITORS SUCH AS 1-ARYL-4-METHYL- [1,2,4] TRIAZOLO [4,3-A] QUINOXALINE COMPOUNDS AND PDE 10 INHIBITORS FOR USE IN THE TREATMENT OF NEUROLOGICAL OR METABOLIC DISORDERS | JANSSEN PHARMACEUTICA NV (BE) | 2014-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140147386-A1 | 1-ARYL-4-METHYL-[1,2,4]TRIAZOLO[4,3-a]QUINOXALINE DERIVATIVES | PDE2A, PDE12, PDE5A | PDE2A 1/4885PDE10A 10/4885 |
| US-10604523-B2 | 1-aryl-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline derivatives | PDE2A, PDE12, PDE5A | PDE2A 1/4885PDE10A 10/4885 |
| US-20150366873-A1 | COMBINATIONS COMPRISING PDE 2 INHIBITORS SUCH AS 1-ARYL-4-METHYL-[1,2,4]TRIAZOLO-[4,3-A]]QUINOXALINE COMPOUNDS AND PDE 10 INHIBITORS FOR USE IN THE TREATMENT OF NEUROLOGICAL OF METABOLIC DISORDERS | PDE12, PDE5A, PDE2A | PDE2A 3/4885PDE10A 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.